---
title: "Aclaris Therapeutics 宣佈 Ati-2138 開放標籤 2A 期試驗取得積極的頂線結果，這是一種強效且選擇性的 Itk 和 Jak3 抑制劑，該試驗達到了主要和關鍵次要終點"
description: "Aclaris Therapeutics Inc：Aclaris Therapeutics 宣佈 ATI-2138 的開放標籤 2A 期試驗取得積極的頂線結果，ATI-2138 是一種強效且選擇性的 ITK 和 JAK3 抑制劑；試驗達成主要和關鍵次要終點。Aclaris Therapeutics Inc - 主要終點確認 ATI-2138 具有良好的耐受性。Aclaris Therapeutic"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/250662154.md"
published_at: "2025-07-29T21:19:54.000Z"
---

# Aclaris Therapeutics 宣佈 Ati-2138 開放標籤 2A 期試驗取得積極的頂線結果，這是一種強效且選擇性的 Itk 和 Jak3 抑制劑，該試驗達到了主要和關鍵次要終點

> Aclaris Therapeutics Inc：Aclaris Therapeutics 宣佈 ATI-2138 的開放標籤 2A 期試驗取得積極的頂線結果，ATI-2138 是一種強效且選擇性的 ITK 和 JAK3 抑制劑；試驗達成主要和關鍵次要終點。Aclaris Therapeutics Inc - 主要終點確認 ATI-2138 具有良好的耐受性。Aclaris Therapeutics Inc - ATI-2138 耐受良好，沒有嚴重不良事件

Aclaris Therapeutics Inc :

-   Aclaris Therapeutics 宣佈 ATI-2138 的開放標籤 2A 期臨牀試驗取得積極的頂線結果，ATI-2138 是一種強效且選擇性的 ITK 和 JAK3 研究性抑制劑；試驗達成主要和關鍵次要終點
-   Aclaris Therapeutics Inc - 主要終點確認 ATI-2138 具有良好的耐受性特徵
-   Aclaris Therapeutics Inc - ATI-2138 耐受良好，沒有嚴重不良事件

### Related Stocks

- [ACRS.US - Aclaris Therap](https://longbridge.com/zh-HK/quote/ACRS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 12:45 ETAxisCare Named to G2's 2026 Best Healthcare Software List | AxisCare has been named to G2's 2026 Best Healthcare Software list, recognized as the top-rated home care management sof | [Link](https://longbridge.com/zh-HK/news/276257162.md) |
| Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 | Aclaris Therapeutics (NASDAQ: ACRS) presented its development priorities and milestones for its biologics and oral small | [Link](https://longbridge.com/zh-HK/news/275827675.md) |
| Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy | Aclaris Therapeutics has expanded its inflammation and immunology pipeline, focusing on innovative therapies for Th1-, T | [Link](https://longbridge.com/zh-HK/news/272270423.md) |
| Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 | Aclaris Therapeutics, Inc. (ACRS) reported positive interim results from a Phase 1a trial of ATI-052, indicating it was  | [Link](https://longbridge.com/zh-HK/news/271653199.md) |
| Ascelia Pharma AB reports full year 2025 operating result of SEK -74.4M, earnings per share of SEK -0.67, and liquid assets of SEK 49.9M | Ascelia Pharma AB reported its full year 2025 financial results, showing an operating result of SEK -74.4 million and ea | [Link](https://longbridge.com/zh-HK/news/274926047.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。